China SXT Pharmaceuticals (SXTC) Receivables - Net (2018 - 2026)

China SXT Pharmaceuticals has reported Receivables - Net for 9 years, with the latest figure at $2.9 million in Q1 2026.

• On a quarterly basis, Receivables - Net fell 15.12% year-over-year to $2.9 million in Q1 2026; TTM through Mar 2026 was $2.9 million, a 15.12% decrease from a year earlier, with the FY2026 full-year figure at $2.9 million, down 15.12% from the prior year.
• Receivables - Net was $2.9 million for Q1 2026 at China SXT Pharmaceuticals, down from $3.3 million in the prior quarter.
• The five-year high for Receivables - Net was $4.1 million in Q1 2022, with the low at $2.8 million in Q3 2023.
• Average Receivables - Net over 5 years is $3.3 million, with a median of $3.3 million recorded in 2025.
• The sharpest annual moves came in 2023 and 2024: Receivables - Net tumbled 30.8% in 2023, then gained 24.38% in 2024.
• Over 5 years, Receivables - Net stood at $4.0 million in 2022, then plunged by 30.8% to $2.8 million in 2023, then advanced by 24.38% to $3.4 million in 2024, then decreased by 2.83% to $3.3 million in 2025, then retreated by 14.21% to $2.9 million in 2026.
• The last three Receivables - Net figures came in at $2.9 million (Q1 2026), $3.3 million (Q3 2025), and $3.4 million (Q1 2025), per Business Quant data.